EU Regulator Backs Sanofi’s Injectable Version of Blood Cancer Drug

Why It Matters

A more convenient injection format can boost patient adherence and expand market share, positioning Sanofi ahead in the competitive multiple myeloma space.

Key Takeaways

• EMA recommends subcutaneous Sarclisa, pending EU Commission approval
• Subcutaneous form shows non‑inferior efficacy to IV version
• On‑body injector simplifies multiple myeloma treatment administration
• Sarclisa generated €588 M ($677 M) in 2025 sales
• FDA also reviewing same formulation for US market

Pulse Analysis

Sanofi’s move to develop a subcutaneous version of Sarclisa reflects a broader industry trend toward patient‑centric drug delivery. Multiple myeloma, a rare but aggressive blood cancer, traditionally requires frequent hospital infusions, which strain both patients and healthcare systems. By leveraging an on‑body injector that administers the medication over time, Sanofi aims to reduce clinic visits, lower infection risks associated with IV lines, and improve overall quality of life for patients undergoing long‑term therapy.

Regulatory momentum is strong. The EMA’s positive opinion, based on robust late‑stage trial data, signals confidence in the drug’s safety and efficacy profile. While the European Commission’s final decision is pending, the timeline suggests market entry could occur within the next few months. Simultaneously, the U.S. FDA’s parallel review underscores the global relevance of this formulation, potentially harmonizing approval pathways and accelerating access across major markets.

From a business perspective, the subcutaneous Sarclisa could revitalize Sanofi’s oncology portfolio. With €588 million ($677 million) in 2025 sales, the drug already commands a solid revenue base. Introducing a more convenient delivery method may capture additional market share, especially as competitors launch oral and injectable therapies for myeloma. Enhanced patient adherence and expanded geographic reach could translate into multi‑digit growth, reinforcing Sanofi’s strategic position in the high‑margin specialty pharma segment.